SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid ...
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is ...
With $31.4 million in new funding, the company will bring the benefits of robotics to one of the few remaining untouched areas of medicine, structural heart SANTA CRUZ, Calif.--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results